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RNA metabolism in uremic patients: Accumulation of modified ribo-
nucleosides in uremic serum. To determine the metabolism of ribonucleic
acid (RNA) in uremia, serum and urine levels of ribonucleosides in uremic
patients were analyzed using reversed-phase high-performance liquid
chromatography. The serum levels of xanthosine and all modified ribo-
nucleosides were increased in undialyzed patients with chronic renal
failure (CRF), and patients undergoing hemodialysis (HD) and continu-
ous ambulatory peritoneal dialysis (CAPD). The serum level of pseudouri-
dine was markedly increased in all the uremic patients especially CAPD
patients (32 times higher than normal). By contrast, the serum level of
adenosine did not show any significant change in the uremic patients.
Interestingly, the serum and urine levels of inosine were significantly
decreased in all the uremic patients, suggesting that the production of
inosine is decreased in uremic patients. The serum level of uridine was
significantly elevated only in the HD patients. The serum levels of all
ribonucleosides except inosine and uridine decreased significantly after
HD. The urinary excretion of inosine, 1-methyladenosine, 1-methyl-
guanosine, N2,N2-dimethylguanosine and N4-acetylcytidine was signifi-
cantly decreased in the CRF patients, leading to the accumulation of these
modified ribonucleosides in the uremic serum. CAPD patients showed
markedly increased serum levels of modified ribonucleosides such as
pseudouridine, 1-methylinosine, and N2,N2-dimethylguanosine and N4-
acetylcytidine as compared with the HD patients. These results demon-
strate that there was an altered metabolism of RNA in uremic patients
with marked accumulation of modified ribonucleosides.
Uremia is an end-stage renal disorder characterized by various
uremic symptoms, which are thought to be caused by accumula-
tion of uremic toxins circulating in the blood. Uremic toxins
include low- to high-molecular-weight substances that accumulate
in blood because of renal insufficiency. With the advances in
analytical techniques, a number of substances that accumulate in
uremic blood have been identified and proposed as uremic toxins.
However, nucleic acid metabolism in uremic patients has not been
studied in detail, because of difficulties in their analysis.
Ribonucleic acid (RNA) is an important biological component.
Methylated purines and pyrimidines and the other modified
ribonucleosides are derived from RNA, especially from transfer
ribonucleic acid (tRNA). Since methylation occurs only after
synthesis of the intact molecule, and no kinases have been found
that will re-incorporate the monomer units into tRNA, the
modified bases and ribonucleosides are excreted into urine fol-
lowing metabolic degradation of tRNA molecules. Modified
ribonucleosides have been shown to be excreted in abnormal
amounts in the urine of patients with a variety of neoplastic
diseases [1, 2]. Furthermore, urinary levels of the modified
ribonucleosides have been suggested as useful markers for mon-
itoring progress of disease and response to therapy. However,
little is known about the changes in the concentration of modified
ribonucleosides in the blood and urine of uremic patients except
pseudouridine (5-ribosyluracil). Pseudouridine derived predomi-
nantly from tRNA is not catabolized but excreted in urine as the
intact molecule. The serum level of pseudouridine has been
reported to be increased in uremic patients [3–6], especially when
they are undergoing continuous ambulatory peritoneal dialysis
(CAPD) [4]. Further analytical study on the metabolism of
modified ribonucleosides in uremic patients is required to shed
light on their possible roles as uremic toxins.
To determine RNA metabolism in uremic patients and the
effects of hemodialysis (HD) and CAPD on the metabolism, we
developed a simple high-performance liquid chromatography
(HPLC) method to measure the serum and urine levels of
ribonucleosides in uremic undialyzed patients, HD patients and
CAPD patients.
METHODS
Chemicals
Pseudouridine (C), 1-methyladenosine (m1A), 1-methylinosine
(m1I), 1-methylguanosine (m1G), N4-acetylcytidine (ac4C), N2-
methylguanosine (m2G), adenosine (A), N6-methyladenosine
(m6A), allopurinol ribonucleoside (APR), 3-methyluridine (m3U)
and 5-bromouridine (br5U) were obtained from Sigma Chemical
Co. (St. Louis, MO, USA). Uridine (U), guanosine (G) and
cytidine (C) were obtained from Kohjin Co. (Tokyo, Japan), and
xanthosine (X) from Nakarai Chemical Co. (Kyoto, Japan).
Inosine (I) was obtained from Wako Pure Chemical Co. (Osaka,
Japan). N2,N2-Dimethylguanosine (m2
2G) was a gift from Dr.
Yamazaki (Ajinomoto Co., Kanagawa, Japan). N6-Threonylcar-
bamoyladenosine (t6A) was synthesized according to the method
of Chheda and Hong [7].
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Patients
Serum samples were obtained from 10 healthy subjects (5 males
and 5 females), 11 undialyzed patients with chronic renal failure
(CRF; 6 males and 5 females), 17 uremic patients on HD (9 males
and 8 females), and 14 uremic patients on CAPD (5 males and 9
females). Serum levels of creatinine in the healthy subjects and
the patients are listed in Table 1. Nutritional status of all the
patients was good from the viewpoint of serum albumin (3.9 6 0.3
g/dl, mean 6 SD; range 3.5 to 4.5 g/dl). Four patients on HD were
complicated with diabetes mellitus. Hemodialysis was performed
using cellulose triacetate (FB-130U; Nipro, Osaka, Japan) dialyz-
ers for four hours three times a week. CAPD was performed by
exchanging 2 liters of dialysate (Dianeal 1.36; Baxter, Round
Lake, IL, USA) four times a day.
Analysis of ribonucleosides
The serum sample (1 ml) in a microsample tube (1.5 ml volume;
Eppendolf) was mixed with m3U (20 nmol) as an internal
standard, and subsequently deproteinized using ultrafiltration
with a membrane filter (Centricut mini V-20, cut-off molecular
weight, 20 kDa; Kurashiki-boseki Co., Okayama, Japan) for 3 to 4
hours by centrifugation at 2000 3 g. The ultrafiltrate was trans-
ferred into another microsample tube, and then mixed with 250 ml
of 2.5 M ammonium acetate (pH 9.0). The mixed solution was
applied into a pretreated boronate gel (Affi-Gel 601; Bio-Rad,
Richmond, CA, USA) column (55 mm 3 5 mm i.d.). After
washing the microsample tube with 500 ml of 0.25 M ammonium
acetate (pH 8.8), the washing solution was also applied to the gel
column. The column was washed with 3 ml of 0.25 M ammonium
acetate (pH 8.8) followed by 0.3 ml of methanol/water (1:1,
vol/vol). Ribonucleosides were eluted from the column with 5 ml
of 0.04 M formic acid in methanol/water (1:1, vol/vol). The eluate
was lyophilized to dryness. The residue was dissolved in 100 ml of
0.1 M ammonium acetate (pH 6.0), and ultrafiltrated with a
membrane filter (Centricut super-mini W-MO, pore size
0.45 mm). The ultrafiltrate (20 ml) was analyzed by HPLC.
Urine sample (250 ml) in a microsample tube (1.5 ml volume;
Eppendolf) was mixed with br5U (10 nmol) as an internal
standard and 100 ml of 2.5 M ammonium acetate (pH 9.0). The
mixed solution was applied into the pretreated boronate gel
column. After washing the microsample tube with 500 ml of 0.25
M ammonium acetate (pH 8.8), the washing solution was also
applied to the gel column. The following procedures were the
same as for the serum samples.
For pretreatment of the boronate gel column, boronate gel (1 g;
Affi-Gel 601) was washed 10 times alternatively with methanol
and water, and then packed into a minicolumn (55 mm 3 5 mm
i.d., miniature champagne columns 4 ml reservoir; Supelco Co.,
Bellefonte, PA, USA) with a glass wool in the bottom. After
washing with 15 ml of 0.25 M ammonium acetate (pH 8.8), the
column was used for the isolation of ribonucleosides.
The chromatograph apparatus (Toyo Soda, Tokyo, Japan)
consisted of a Model CCP controller PX-8010, a Model CCPD
dual pump, a Model GE-8000 gradienter, a Model MX-8010
mixer, a Model ERC-3415 degasser, a Model UV-8000 ultraviolet
Table 1. Serum levels of ribonucleosides in healthy subjects and uremic patients
N
Normal
10
CRF
11
HD
CAPD
14
ANOVA
P value
Before
17
After
17
Major ribonucleosides and
their metabolites
nmol/liter
A 130 6 20 140 6 40 220 6 50 110 6 20e 130 6 10 NS
I 5000 6 800 1600 6 400b 3300 6 500a 2900 6 600a 3000 6 500a ,0.01
X 84 6 15 340 6 70b 250 6 40b 150 6 20f 240 6 30b ,0.01
U 5000 6 400 6200 6 800 7000 6 600a 7300 6 600a 5100 6 500c ,0.05
Modified ribonucleosides
nmol/liter
C 1700 6 100 29000 6 5000b 28000 6 2000b 12000 6 1000af 55000 6 6000bd ,0.01
m1A 61 6 6 220 6 430b 370 6 50b 150 6 10f 310 6 10b ,0.01
m6A 66 6 10 250 6 60b 250 6 40b 130 6 20f 180 6 30 ,0.01
t6A 94 6 24 590 6 130b 1000 6 100b 280 6 30f 700 6 50bd ,0.01
m1I 48 6 14 880 6 130b 1200 6 100b 570 6 40bf 2200 6 200bd ,0.01
m1G 46 6 19 99 6 21 140 6 20b 78 6 10f 120 6 20b ,0.01
m2
2G 29 6 5 440 6 90b 570 6 50b 270 6 30af 760 6 80bc ,0.01
ac4C 200 6 20 250 6 30 350 6 40b 150 6 10f 560 6 30bd ,0.01
Serum creatinine
mmol/liter
78 6 3 840 6 150 1010 6 50b 430 6 20f 860 6 60 ,0.01
Abbreviations are: A, adenosine; ac4C, N4-acetylcytidine; I, inosine; m1A, 1-methyladenosine; m1G, 1-methylguanosine; m1I, 1-methylinosine; m2
2G,
N2,N2-dimethylguanosine; m6A, N6-methyladenosine; t6A, N6-threonylcarbamoyladenosine; U, uridine; X, xanthosine; C, pseudouridine.
a P , 0.05, b P , 0.01 vs. normal by Fisher’s PLSD test
c P , 0.05, d P , 0.01 vs. before HD by Fisher’s PLSD test for comparison between before HD and CAPD
e P , 0.05, f P , 0.01 as compared with before HD by paired t-test
Table 2. The mobile phase consisting of solution (A) (0.1 M
ammonium acetate, pH 6.0) and solution (B) (methanol/water, 40:60,
vol/vol)
Time min 0 3 5 25 30 34 37 45 48 53
%B 0 0 10 25 50 75 75 100 100 0
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detector, a Model Chromatopack C-R64 (Shimadzu, Kyoto, Ja-
pan), and a reverse phase column (Develosil ODS-UG-5, 250
mm 3 4.6 mm I.D.; Nomura Chemical Co., Aichi, Japan) with a
guard column (Develosil ODS-UG-5, 30 mm 3 4.6 mm I.D.). The
mobile phase, consisting of solution (A) (0.1 M ammonium
acetate, pH 6.0) and solution (B) (methanol/water, 40:60, vol/vol),
was delivered at a flow rate of 1 ml/min at ambient temperature.
The mobile phase was programmed (Table 2), and the eluate was
monitored by detecting ultraviolet at 254 nm.
Calibration was done using standard solutions containing ribo-
nucleosides in distilled water at five different concentrations for
each ribonucleoside. The calibration lines showed strong correla-
tions (r ^ 0.999).
Identification of ribonucleosides was confirmed by liquid chro-
matography/mass spectrometry (LC/MS) with frit-fast atom bom-
bardment (FAB) [8, 9].
Statistical analysis
Results are expressed as the mean 6 SE. Statistical analysis was
done using analysis of variance (ANOVA) for multiple compari-
son, unpaired t-test for two groups between normal subjects and
CRF patients, and paired t-test for two groups between before
and after HD. Differences were considered statistically significant
when the P value was less than 0.05.
RESULTS
Serum levels of ribonucleosides
Figure 1 shows the HPLC chromatograms of serum ribonucleo-
Fig. 1. High-performance liquid chromatography (HPLC) of serum ribonucleosides in a healthy subject (A), a chronic renal failure (CRF) patient (B),
a hemodialysis (HD) patient, (C) and a continuous ambulatory peritoneal dialysis (CAPD) patient (D). The peaks were identified as follows: (1.)
5,6-dihydrouridine (D); (2.) pseudouridine (C); (3.) cytidine (C); (4.) 3-(3-amino-3-carboxypropyl)uridine (acp3U); (5.) uridine (U); (6.) 1-methylad-
enosine (m1A); (7.) xanthosine (X); (9.) inosine (I); (11.) 4-pyridone-3-carboxamide-N1-ribofuranoside (PCNR); (14.) 1-methylinosine (m1I); (15.)
1-methylguanosine (m1G); (16.) N4-acetylcytidine (ac4C); (17.) N2-methylguanosine (m2G:); (18.) adenosine (A); (19.) N2,N2-dimethylguanosine (m2
2G);
(20.) 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2U); (21.) N6-threonylcarbamoyladenosine (t6A); (22.) N6-methyladenosine (m6A); (23.) N6-
methyl-N6-threonylcarbamoyladenosine (mt6A). The abbreviation IS is the internal standard (3-methyluridine: m3U).
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sides in a healthy subject (a), a CRF patient (b), an HD patient (c)
and a CAPD patient (D). The concentration of guanosine and
cytidine in the serum and urine could not be determined using
HPLC because of their trace levels. Table 1 summarizes the serum
levels of ribonucleosides in healthy subjects and uremic patients.
The serum levels of xanthosine and all modified ribonucleosides
were increased in CRF, HD and CAPD patients as compared with
healthy subjects. The serum levels of pseudouridine were mark-
edly increased in all the uremic patients especially undergoing
CAPD. However, the serum levels of adenosine did not show any
significant change in the uremic patients compared with those in
healthy subjects. Interestingly, the serum level of inosine was
significantly decreased in the uremic patients, especially CRF
patients. The serum level of uridine was significantly elevated only
in HD patients. The serum levels of all ribonucleosides except
inosine and uridine decreased significantly after HD.
CAPD patients showed significantly increased serum levels of
pseudouridine, m1I, m2
2G and ac4C, and decreased serum levels of
uridine and t6A as compared with HD patients. The molar ratio of
serum pseudouridine (mmol/liter) to serum creatinine (mmol/
liter) in CAPD patients (0.068 6 0.01) was significantly (P , 0.01
by Fisher’s PLSD test) increased as compared with those in HD
patients (pre-HD 0.028 6 0.002; post-HD 0.029 6 0.002), CRF
patients (0.037 6 0.002) and normal subjects (0.022 6 0.001;
ANOVA, P , 0.01). There was no significant difference in the
serum levels of pseudouridine between high and low transporters
among CAPD patients.
Table 3 shows the correlation coefficients between serum levels
of creatinine and ribonucleosides in CRF and all the dialysis
patients. In CRF patients the serum levels of creatinine showed
significantly positive correlation with pseudouridine (r 5 0.951),
m1I, t6A and m2
2G, and also showed a tendency of positive
correlation with xanthosine and ac4C. In all the dialysis patients,
pseudouridine was positively, but not equally well, correlated (r 5
0.446) with serum creatinine.
Urinary excretion of ribonucleosides
Figure 2 shows the HPLC chromatograms of urine ribonucleo-
sides in a healthy subject (Fig. 2A) and a CRF patient (Fig. 2B).
Table 4 summarizes urinary excretion of the ribonucleosides in
healthy subjects and CRF patients. Urinary excretion of inosine,
m1A, m1G, m2
2G and ac4C was significantly decreased in the CRF
patients. Both urine and serum levels of inosine were decreased in
Fig. 2. HPLC chromatograms of urine ribonucleosides in a healthy
subject (A) and a chronic renal failure patient (B). The peaks are
identified as follows: (1.) 5,6-dihydrouridine (D); (2.) pseudouridine (c);
(3.) cytidine (C); (4.) 3-(3-amino-3-carboxypropyl)uridine (acp3U); (5.)
uridine (U); (6.) 1-methyladenosine (m1A); (7.) xanthosine (X); (8.)
7-methylguanine (m7Gua), (9.) inosine (I); (10.) 7-methylguanosine
(m7G); (11.) 4-pyridone-3-carboxamide-N1-ribofuranoside (PCNR); (12.)
guanosine (G); (13.) 3-methyluridine (m3U); (14.) 1-methylinosine (m1I);
(15.) 1-methylguanosine (m1G); (16.) N4-acetylcytidine (ac4C); (17.) N2-
methylguanosine (m2G:); (18.) adenosine (A); (19.) N2,N2-dimethyl-
guanosine (m2
2G); (20.) 5-methoxycarbonylmethyl-2-thiouridine (mcm5
s2U); (21.) N6-threonylcarbamoyladenosine (t6A); (22.) N6-methylad-
enosine (m6A); (23.) N6-methyl-N6-threonylcarbamoyladenosine (mt6A);
(24.) N6-threonylcarbamoyl-2-methylthioadenosine (ms2t6A). Abbrevia-
tion IS is the internal standard (5-bromouridine: br5U).
Table 3. Correlation between serum creatinine and serum
ribonucleosides in chronic renal failure (CRF) and dialysis patients
CRF
(N 5 11)
Dialysis patients
(before and after
HD, CAPD)
(N 5 48)
r P r P
Major ribonucleosides
and their
metabolites
A 20.05 NS 0.348 ,0.05
I 0.131 NS 0.073 NS
X 0.597 ,0.1 0.383 ,0.01
U 0.352 NS 20.16 NS
Modified
ribonucleosides
C 0.951 ,0.01 0.446 ,0.01
m1A 0.423 NS 0.46 ,0.01
m6A 0.556 ,0.1 0.295 ,0.05
t6A 0.92 ,0.01 0.726 ,0.01
m1I 0.927 ,0.01 0.466 ,0.01
m1G 0.615 ,0.1 0.314 ,0.05
m2
2G 0.744 ,0.01 0.439 ,0.01
ac4C 0.541 ,0.1 0.49 ,0.01
Abbreviations are: A, adenosine; ac4C, N4-acetylcytidine; I, inosine;
m1A, 1-methyladenosine; m1G, 1-methylguanosine; m1I, 1-methylinosine;
m2
2G, N2,N2-dimethylguanosine; N6A, N6-methyladenosine; t6A, N6-threo-
nylcarbamoyladenosine; U, uridine; X, xanthosine; C, pseudouridine; NS,
not significant.
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the CRF patients, suggesting that the production of inosine in
uremic patients is decreased. The decreased urinary excretion of
m1A, m1G, m2
2G and ac4C led to the accumulation of these
modified ribonucleosides in the uremic serum.
DISCUSSION
We developed an HPLC method for quantification of serum
and urine ribonucleosides, and demonstrated that the serum
levels of xanthosine and all modified ribonucleosides, especially
pseudouridine, were increased in uremic patients. Hemodialysis
decreased the serum levels of all the ribonucleosides except
inosine and uridine. The serum levels of most modified ribo-
nucleosides were significantly higher in CAPD patients than in
HD patients. By contrast, there was no significant change in the
serum levels of adenosine in the uremic patients. Interestingly, the
serum and urine levels of inosine were rather low in uremic
patients.
The serum levels of pseudouridine were markedly elevated in
uremic patients, especially CAPD patients (32 times higher than
normal), as reported previously [4]. The lower weekly creatinine
clearance in CAPD patients than in HD patients cannot explain
the markedly increased serum levels of pseudouridine in CAPD
patients, because the molar ratio of serum pseudouridine to
creatinine was 2.4 times higher in CAPD patients as compared
with HD patients. The marked increase in pseudouridine levels in
CAPD patients can be explained by lower transport rate of
pseudouridine when compared with that of HD probably due to
glucose-induced molecular self-association of pseudouridine in
the peritoneal membrane [10].
Pseudouridine is reported to inhibit basal and insulin-stimu-
lated glucose utilization in isolated rat soleus muscle in vitro, and
is considered to be responsible for insulin resistance in uremia
[11–13]. Pseudouridine is a modified ribonucleoside originating
almost exclusively from the catabolism of tRNA. Once released
from tRNA, it is not reincorporated into the other molecules of
tRNA, and excreted into urine as an end product. Consequently,
pseudouridine accumulates in uremic serum due to the impair-
ment of its renal excretion and increased tubular reabsorption [5],
but not due to the increased synthesis. We confirmed their results
[5] that the serum level of pseudouridine was markedly increased
and its urinary excretion was slightly decreased in uremic patients.
A marked increase of pseudouridine in cerebrospinal fluid was
also observed in young uremic children [14], and was considered
to have some relationship with delayed cognitive development in
the patients. Further study is required to establish the role of
pseudouridine as a uremic toxin.
The serum levels of the other modified ribonucleosides were
also increased in uremic patients especially undergoing CAPD,
and showed positive correlation with serum creatinine in CRF
patients. Since these modified nucleosides like pseudouridine are
the end products of RNA especially of tRNA and are not
re-incorporated into newly synthesized RNA molecules, they are
normally excreted into urine. However, in uremia they accumulate
in the blood due to their reduced renal clearance. By contrast, the
serum levels of adenosine, uridine and inosine were not elevated
in uremic patients except uridine in HD patients, presumably
because these major ribonucleoside can be re-utilized for the
synthesis of their phosphates. Xanthosine, a product from xanth-
ylic acid, is metabolized into xanthine, followed by its conversion
into uric acid. Uric acid is normally excreted into urine, and
accumulates in uremic serum. The accumulation of uric acid in
uremic serum may lead to elevation of serum xanthosine level.
The serum level of uridine was elevated in HD patients, although
the mechanism is not clear. It is of note that uridine is demon-
strated to act as a sleep-promoting substance by its intraventric-
ular infusion or even by intraperitoneal infusion [15–17], and to
induce hyperthermia [18]. Thus, the increase of uridine level
caused by HD may be related to sleep disorder and hyperthermia
in HD patients.
In conclusion, our study demonstrates that there are extensively
altered metabolism of RNA-derived products with marked accu-
mulation of modified ribonucleosides in uremic patients. How-
ever, further studies are required to elucidate their role in the
development of specific uremic symptoms.
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APPENDIX
Abbreviations used in this paper are: A, adenosine; ac4C, N4-acetylcy-
tidine; acp3U, 3-(3-amino-3-carboxypropyl)uridine; br5U, 5-bromouri-
dine; C, cytidine; CAPD, continuous ambulatory peritoneal dialysis; CRF,
chronic renal failure; D, 5,6-dihydrouridine; FAB, fast atom bombard-
ment; G, guanosine; HD, hemodialysis; HPLC, high-pressure liquid
chromatography; I, inosine; LC/MS, liquid chromatography/mass specto-
metry; m1A, 1-methyladenosine; m1G, 1-methylguanosine; m1I, 1-methyl-
inosine; m2G, N2-methylguanosine; m2
2G, N2,N2-dimethylguanosine; m3U,
3-methyluridine; m6A, N6-methyladenosine; m7G, 7-methylguanosine;
Table 4. Urine levels of ribonucleosides in healthy subjects and uremic
patients
N
mmol/day
Normal
10
CRF
11
Major ribonucleosides and their metabolites
A 2.4 6 0.5 2.1 6 0.5
I 5.4 6 0.6 2.0 6 0.6b
X 4.6 6 0.4 9.4 6 4.0
U 3.1 6 0.3 7.3 6 2.3
Modified ribonucleosides
C 200 6 10 180 6 30
m1A 18 6 1 4.7 6 1.3b
m6A 0.85 6 0.09 1.2 6 0.3
t6A 5.5 6 0.4 4.6 6 1.0
m1I 15 6 1 17 6 4
m1G 9.5 6 0.8 2.4 6 0.7b
m2
2G 12 6 1 6.9 6 1.4b
ac4C 9.2 6 1.0 5.0 6 1.2a
Abbreviations are: A, adenosine; ac4C, N4-acetylcytidine; I, inosine;
m1A, 1-methyladenosine; m1G, 1-methylguanosine; m1I, 1-methylinosine;
m2
2G, N2,N2-dimethylguanosine; m6A, N6-methyladenosine; t6A, N6-
threonylcarbamoyladenosine; U, uridine; X, xanthosine, C, pseudouri-
dine.
a P , 0.05 vs. normal by unpaired t-test
b P , 0.01 vs. normal by unpaired t-test
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m7Gua, 7-methylguanine; ms2t6A, N6-threonylcarbamoyl-2-methylthio-
adenosine; mcm5 s2U, 5-methoxycarbonylmethyl-2-thiouridine; mt6A, N6-
methyl-N6-threonylcarbamoyladenosine; PCNR, 4-pyridone-3-carbox-
amide-N1-ribofuranoside; t6A, N6-threonylcarbamoyladenosine; U,
uridine; X, xanthosine; C, pseudouridine.
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